Aptinyx to Report Third Quarter Financial Results on Thursday, November 12, 2020
Aptinyx Inc. (Nasdaq: APTX) announced a conference call on November 12, 2020, at 5:00 p.m. ET to discuss its third quarter financial results and business highlights. The call can be accessed domestically at (833) 772-0394 and internationally at (236) 738-2205 using conference ID 9186375. The company is focused on developing therapies for brain and nervous system disorders and has three candidates in clinical development targeting chronic pain, PTSD, and cognitive impairment linked to Parkinson's disease.
- Aptinyx has three product candidates in clinical development targeting significant CNS disorders.
- The company's unique NMDA receptor modulation platform may lead to innovative therapies.
- None.
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, November 12, 2020 at 5:00 p.m. ET to report third quarter 2020 financial results and discuss recent business highlights.
To access the live conference call, please dial (833) 772-0394 (domestic) or (236) 738-2205 (international) and refer to conference ID 9186375. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx’s website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx’s website for 30 days following the event.
About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson’s disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.
Source: Aptinyx Inc.
